Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
Publication Date: November 29, 2018
Key Points
Key Points
Women with node-positive breast cancer should receive extended therapy including an aromatase inhibitor (AI) for up to a total of 10 years of adjuvant endocrine treatment.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Treatment
...reatme...
Updated Recommendations on Extended Thera...
...node-negative breast cancer are potential candida...
...omen with node-positive breast canc...
...g extended adjuvant endocrine therapy sh...
...of secondary or contralateral breast...
...ended therapy carries ongoing risks and side...
...ndations on Ovarian Suppres...
The Panel recommends that higher risk patien...
...Stage II or Stage III breast cancers who wou...
...tage I or II breast cancers at higher risk o...
...I breast cancers not warranting chemotherapy shou...
...ode-negative cancers 1 centimeter or l...
...ian suppression may be administered with either...
...1. Recommended Pharmaceuticals for HR+ Breast Canc...
...ble 2. Prognostic Factors for Recurrence Af...